| Latest Forum Topics / Biosensors |
 Post Reply
|
|
Is Biosensors a good buy?
|
|||||
|
New123
Elite |
31-Jul-2013 12:03
|
||||
|
x 0
x 0 Alert Admin |
think they will issue a US$ cheque to u.
|
||||
| Useful To Me Not Useful To Me | |||||
|
cycy818
Member |
30-Jul-2013 23:36
|
||||
|
x 0
x 0 Alert Admin |
gut feeling the price will up.... hopefully.... < img src=" http://www.biosearch.co.il/wp-content/uploads/2011/04/D-SPECT-Machine.jpg" alt=" spectrum" /> | ||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
DrEaMzZz
Member |
30-Jul-2013 23:18
|
||||
|
x 0
x 0 Alert Admin |
Tmr XD, will the share price down by US$ 0.02 and how they convert US$ 0.02 to Sing dollar?
|
||||
| Useful To Me Not Useful To Me | |||||
|
New123
Elite |
30-Jul-2013 22:57
|
||||
|
x 0
x 0 Alert Admin |
collect dividend US0.02 1st. think it may goes back to $1.20 level.. | ||||
| Useful To Me Not Useful To Me | |||||
|
cycy818
Member |
30-Jul-2013 22:44
|
||||
|
x 0
x 0 Alert Admin |
NOMURA Securities says ...
BIOSENSORS INTERNATIONAL | BUY | TP: S$1.80
We caught up with the management of Biosensors at its AGM yesterday and highlight the following takeaways:
Management indicated that it will continue to be on the lookout for M& A opportunities to grow the group into a global medical devices platform group
The acquisition of Spectrum Dynamics (SD) provides an opportunity for the group to broaden its offering in the cardiovascular space
The SD imaging machine could potentially help doctors ascertain the appropriate treatment for patients with heart disease
A trial is being conducted in Japan to confirm the applications that the SD imaging machine can offer
As at 31 March 2013, Biosensors has a net cash position of US$337m
Management appeared confident of its guidance of 15% growth in product revenue, underpinned by its core DES business as it gains market share in spite of a stagnating global DES market
Biosensors will launch 4 new products this year including Biomatrix Neoflex, BioFreedom and two balloon catheters under license from Eurocor
Through joint marketing efforts with Terumo, Biosensors hopes to stabilize its market position in Japan and improve sales
Plans are underway to seek regulatory approval for BioFreedom in Japan
To a question from a shareholder if the group will address the US market, management indicated that while the US market is attractive, the group will need to find the best way to address the market eventually
Enrolment for both its LEADERS FREE and GLOBAL LEADERS trials are progressing well
(LEADERS Free is a prospective, randomized double blind trial between a DES and a bare metal stent involving patients with high risk of bleeding
The primary end point is safety with one month course of DAPT.)
The data from LEADERS FREE will be used to support the marketing of BioFreedom
We reiterate our Buy Rating for Biosensors with price target of S$1.80
The shares look attractively valued at 12x FY2014 EPS with an earnings CAGR of 11% over the next 3 years
|
||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
yiming2000
Senior |
25-Jul-2013 22:49
|
||||
|
x 0
x 0 Alert Admin |
I attended the AGM today. There was a lot of anger over loss of shareholder value by one guy who shouted that if othing is done, soon Biosensors will become a penny stock. Anyway, I dare not look at my paper losses. You may like to know that another shareholder pointed out that the Chairman does not have a substantial stock holding anymore. He must have been that mysterious BB who was dumping it. I noticed that 80% of Biosensors stocks are held by top 7 shareholders - all China investment companies. Any smart guys want to figure out what monkey business is going on here?  |
||||
| Useful To Me Not Useful To Me | |||||
|
junction
Senior |
11-Jul-2013 22:25
|
||||
|
x 0
x 0 Alert Admin |
Anyone wants to attend the AGM to vote against the payment of directors fees can have my proxies. The kelong directors don deserve it.
|
||||
| Useful To Me Not Useful To Me | |||||
|
New123
Elite |
11-Jul-2013 14:33
|
||||
|
x 0
x 0 Alert Admin |
gd! CD will drive the shares prices higher..i am in.
|
||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
shadowmoon
Veteran |
11-Jul-2013 07:18
Yells: "Henshin" |
||||
|
x 0
x 0 Alert Admin |
Nomura reiterates $1.80 target for BiosensorsAnalysts: Jit Soon Lim, CFA, & Wen Jie ChanBiosensor's Axxess stent in a blood vessel.Illustration from companyWe lower our earnings for FY14F and FY15F by 6% to reflect the higher costs the group will likely incur as it expands its product base and supports its newly acquired medical imaging business. The higher costs, in our view, will be mitigated by stronger revenue growth from new product launches. We forecast EPS growth of 8% this year before accelerating to 15% CAGR over the following two years. We reiterate our Buy rating with a price target of SGD1.80.Shares oversold following “disappointing” 4Q results. Biosensors has pulled back by 9% post the 4Q results at the end of May. Valuations are attractive, in our view, at 12x FY14 EPS, underpinned by our sum-of-the-parts valuation of SGD1.80 per share and net cash of USD337mn (SGD0.25 per share). In addition, the group will pay a dividend of USD0.02/share by early August 2013 | ||||
| Useful To Me Not Useful To Me | |||||
|
halleluyah
Elite |
08-Jul-2013 17:31
|
||||
|
x 0
x 0 Alert Admin |
Finally gives dividend USD 0.02. |
||||
| Useful To Me Not Useful To Me | |||||
|
Octavia
Elite |
04-Jul-2013 10:06
|
||||
|
x 0
x 0 Alert Admin |
Maybank-KE maintains Hold with $ Not time for re-entry, Maintain Hold with $1.17 TP and caution investors that its not time to reenter yet. While share price is at 24% off its 52-wk peak of SGD1.42, flag further risks in licensing revenue from Terumo which could cap share price recovery. More aggressive marketing efforts for Nobori stent in Japan could result in higher distribution cost. House cut FY3/14F-16F net profits by 6-7% as it raise distribution cost assumptions which were too conservative. Think that share price appreciation in the near-term may still be capped despite the price decline due to the mentioned risks. Norges Bank and Atlantis Capital have recently trimmed their positions with the former ceasing to be a substantial shareholder | ||||
| Useful To Me Not Useful To Me | |||||
|
GorgeousOng
Elite |
04-Jul-2013 10:06
Yells: "Hehehaha...enjoy life n live to the fullest..." |
||||
|
x 0
x 0 Alert Admin |
Biosensors International - More Risks to Licensing Revenue
Author: kimeng | Publish date: Thu, 4 Jul 09:22 Not time for re-entry, Maintain Hold. While share price is at 24% off its 52-wk peak of SGD1.42, we flag further risks in licensing revenue from Terumo which could cap share price recovery. More aggressive marketing efforts for Nobori stent in Japan could result in higher distribution cost. We cut FY3/14F-16F net profits by 6-7% as we raise our distribution cost assumptions which were too conservative. Not time for re-entry, maintain Hold, SOTP-based TP trimmed to SGD1.17. Terumo developing in-house DES. We note in Terumo’s “The New Mid-Term Plan (FY2013 – FY2016)” dated May 2013 that a new Drug Eluting Stent (DES) was introduced in its product pipelines. Based on our checks, a clinical trial has been initiated by Terumo for a new DES named “Discovery123/TCD-10023”, which is expected to be completed in 2014. We believe that this could be the same DES mentioned in Terumo’s plans. We suspect that this is intended to eventually replace the Nobori DES once the licensing agreement with Biosensors expires in 2016. We believe that Biosensors had foreseen this and this could be the part of the reason why it is building up its own sales team in Japan. Licensing income from Terumo accounts for ~15% of FY3/14F revenue but ~45% of net profit. Our TP has been substantially lower than consensus as we valued licensing based on DCF only until 2016. Hard to quantify long term potential. Biosensors has a sound business strategy to transform into a multi-product platform and we recognise the long-term potential that could arise if it is successful. The company has been buying back its shares during the price decline, affirming their confidence. Biosensors still has over USD500m in cash which we believe is mostly earmarked for acquisitions. However, given the difficulties in quantifying the long-term potential and risks from M&As without more clarity, we have been holding back our optimism. Maintain Hold, await positive catalysts. We think that share price appreciation in the near-term may still be capped despite the price decline due to the mentioned risks. Norges Bank and Atlantis Capital have recently trimmed their positions with the former ceasing to be a substantial shareholder. Maintain Hold, with TP reduced to SGD1.17. We await value accretive M&As as potential catalysts for upgrade. Source: Maybank Research - 4 Jul 2013 Labels: Biosensors |
||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
New123
Elite |
02-Jul-2013 22:49
|
||||
|
x 0
x 0 Alert Admin |
Think it will cont to move up..
|
||||
| Useful To Me Not Useful To Me | |||||
|
ongahhuat888
Member |
02-Jul-2013 13:11
|
||||
|
x 0
x 0 Alert Admin |
KIV | ||||
| Useful To Me Not Useful To Me | |||||
|
gbleng
Member |
27-Jun-2013 14:10
|
||||
|
x 0
x 0 Alert Admin |
Another married deal of 1m at 1.07 | ||||
| Useful To Me Not Useful To Me | |||||
|
teobl9
Member |
27-Jun-2013 13:23
|
||||
|
x 0
x 0 Alert Admin |
Company share buy back or BB start moving in? | ||||
| Useful To Me Not Useful To Me | |||||
|
gbleng
Member |
27-Jun-2013 12:17
|
||||
|
x 0
x 0 Alert Admin |
Married deal 1m shares at 1.07 | ||||
| Useful To Me Not Useful To Me | |||||
|
rbgmauq
Member |
26-Jun-2013 21:05
|
||||
|
x 0
x 0 Alert Admin |
Technically,Biosensors (B20) is upgraded to a buy with the 1.36 target price in six months. is uhttp://sgx.stoxline.com/quote.php?s=b20 | ||||
| Useful To Me Not Useful To Me | |||||
|
New123
Elite |
26-Jun-2013 20:37
|
||||
|
x 0
x 0 Alert Admin |
U turn liao. Will go higher tmr | ||||
| Useful To Me Not Useful To Me | |||||
|
starlene
Elite |
21-Jun-2013 18:24
|
||||
|
x 0
x 0 Alert Admin |
Yiming2000 for u..Notice it remains quite strong at 44cts,on April 2013,SIC has approved the whitewash waiver for the land aquisition in the Iskandar Region,one of the conditions pertaining to this land aquisition.The 2nd half of this year,probably soon 2 free warrants for every 1 existing shares held,the warrants can be exercised into mother shares at $0.18..should head higher once shareholders approved but on Mon June 24 is the normal AGM  I went in to buy again 43-44cts after taking quick profit...Biosensor latest shareinvestercom mag..break $1.08 downside expected next critical support $0.75 but put a stop should it moved > $1.08..wow recommending to short Biosensor??? maybe true limited upside but once economic bad news this sicko get shotdown again
|
||||
| Useful To Me Not Useful To Me | |||||